Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity

Biochemical Pharmacology

Volumn 65, Issue 7, 2003, Pages 1129-1137

  Pluquet, Olivier ^a   North, Sophie ^a,c   Richard, Marie Jeanne ^b   Hainaut, Pierre ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b HÔPITAL MICHALLON   (France)

^c INSERM   (France)

Author keywords

Cytoprotection; DNA damage pathway; Oxidation reduction; p53; Polyamines; WR1065

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; AMINOTHIOL; CYSTEINE PROTEINASE; DNA; DNA FRAGMENT; GLUTATHIONE; ONCOPROTEIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

ARTICLE; BINDING AFFINITY; CELL PROTECTION; CELL STRAIN MCF 7; COMET ASSAY; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID PEROXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0037378392     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01655-6     Document Type: Article

References (48)

1. Calabro-Jones P.M., Fahey R.C., Smoluk G.D., Ward J.F. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 47:1985;23-27.
2. Kemp G., Rose P., Lurain J., Berman M., Manetta A., Roullet B., Homesley H., Belpomme D., Glick J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol. 14:1996;2101-2112.
3. Poplin E.A., LoRusso P., Lokich J.J., Gullo J.J., Leming P.D., Schulz J.J., Veach S.R., McCulloch W., Baker L., Schein P. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother. Pharmacol. 33:1994;415-419.
4. Schiller J.H., Storer B., Berlin J., Wittenkeller J., Larson M., Pharo L., Larson M., Berry W. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J. Clin. Oncol. 14:1996;1913-1921.
5. Treskes M., Holwerda U., Klein I., Pinedo H.M., van der Vijgh W.J. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochem. Pharmacol. 42:1991;2125-2130.
6. Douay L., Hu C., Giarratana M.C., Gorin N.C. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. Eur. J. Cancer. 31A(Suppl. 1):1995;S14-S16.
7. List A.F., Heaton R., Glinsmann-Gibson B., Capizzi R.L. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin. Oncol. 23:1996;58-63.
8. Capizzi R.L., Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int. J. Hematol. 72:2000;425-435.
9. Marzatico F., Porta C., Moroni M., Bertorelli L., Borasio E., Finotti N., Pansarasa O., Castagna L. In vitro antioxidant properties of amifostine (WR-2721 Ethyol). Cancer Chemother. Pharmacol. 45:2000;172-176.
10. Nagy B., Dale P.J., Grdina D.J. Protection against cis-diamminedichloroplatinum cytotoxicity and mutagenicity in V79 cells by 2-[(aminopropyl)amino]ethanethiol. Cancer Res. 46:1986;1132-1135.
11. Grdina D.J., Nagy B., Hill C.K., Wells R.L., Peraino C. The radioprotector WR1065 reduces radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cells. Carcinogenesis. 6:1985;929-931.
12. List A.F., Heaton R., Glinsmann-Gibson B., Capizzi R.L. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia. 12:1998;1596-1602.
13. Capizzi R.L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Eur. J. Cancer. 32A(Suppl. 4):1996;S5-S16.
14. Durand R.E. Radioprotection by WR-2721 in vitro at low oxygen tensions: implications for its mechanisms of action. Br. J. Cancer. 47:1983;387-392.
15. Murley J.S., Constantinou A., Kamath N.S., Grdina D.J. WR-1065 an active metabolite of the cytoprotector amifostine affects phosphorylation of topoisomerase II alpha leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Prolif. 30:1997;283-294.
16. Grdina D.J., Constantinou A., Shigematsu N., Murley J.S. Inhibition of topoisomerase II alpha activity in CHO K1 cells by 2-[(aminopropyl)amino]ethanethiol (WR-1065). Radiat. Res. 138:1994;44-52.
17. Snyder R.D., Grdina D.J. Further evidence that the radioprotective aminothiol, WR-1065, catalytically inactivates mammalian topoisomerase II. Cancer Res. 60:2000;1186-1188.
18. Liu S.C., Murley J.S., Woloschak G., Grdina D.J. Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis. 18:1997;2457-2459.
19. Woloschak G.E., Paunesku T., Chang-Liu C.M., Grdina D.J. Expression of thymidine kinase messenger RNA and a related transcript is modulated by radioprotector WR1065. Cancer Res. 55:1995;4788-4792.
20. Murley J.S., Kataoka Y., Hallahan D.E., Roberts J.C., Grdina D.J. Activation of NFkappaB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells. Free Radic. Biol. Med. 30:2001;1426-1439.
21. North S., El Ghissassi F., Pluquet O., Verhaegh G., Hainaut P. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene. 19:2000;1206-1214.
22. Pluquet O., Hainaut P. Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett. 174:2001;1-15.
23. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
24. Hainaut P., Mann K. Zinc binding and redox control of p53 structure and function. Antioxid. Redox Signal. 3:2001;611-623.
25. Wahl G.M., Carr A.M. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat. Cell Biol. 3:2001;E277-E286.
26. Balint E.E., Vousden K.H. Activation and activities of the p53 tumour suppressor protein. Br. J. Cancer. 85:2001;1813-1823.
27. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
28. Shen H., Chen Z.J., Zilfou J.T., Hopper E., Murphy M., Tew K.D. Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. J. Pharmacol. Exp. Ther. 297:2001;1067-1073.
29. Verhaegh G.W., Richard M.-J., Hainaut P. Regulation of p53 by metal ions and by antioxidants: dithiocarbamate down-regulates p53 DNA-binding activity by increasing the intracellular level of copper. Mol. Cell Biol. 17:1997;5699-5706.
30. Meplan C., Richard M.-J., Hainaut P. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene. 19:2000;5227-5236.
31. Emonet-Piccardi N., Richard M.-J., Ravanat J.L., Signorini N., Cadet J., Beani J.C. Protective effects of antioxidants against UVA-induced DNA damage in human skin fibroblasts in culture. Free Radic. Res. 29:1998;307-313.
32. Akerboom T.P., Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol. 77:1981;373-382.
33. Meier T., Issels R.D. Degradation of 2-(3-aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence on glutathione status of Chinese hamster ovary cells. Biochem. Pharmacol. 50:1995;489-496.
34. Alarcon R., Koumenis C., Geyer R.K., Maki C.G., Giaccia A.J. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 59:1999;6046-6051.
35. Polla B.S., Donati Y., Kondo M., Tochon-Danguy H.J., Bonjour J.P. Protection from cellular oxidative injury and calcium intrusion by N-(2-mercaptoethyl)-1,3-propanediamine, WR 1065. Biochem. Pharmacol. 40:1990;1469-1475.
36. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 21:1993;3167-3174.
37. Hainaut P., Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53:1993;4469-4473.
38. Nelson W.G., Kastan M.B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell Biol. 14:1994;1815-1823.
39. Rainwater R., Parks D., Anderson M.E., Tegtmeyer P., Mann K. Role of cysteine residues in regulation of p53 function. Mol. Cell Biol. 15:1995;3892-3903.
40. North S., Pluquet O., Maurici D., El Ghissassi F., Hainaut P. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol. Carcinogen. 33:2002;181-188.
41. Maurici D., Monti P., Campomenosi P., North S., Frebourg T., Fronza G., Hainaut P. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene. 20:2001;3533-3540.
42. Pluquet O, North S, Bhoumik A, Dimas K, Ronai Z, Hainaut P. The cytoprotective aminothiol WR1065 activates p53 through a non genotoxic signaling pathway involving c-jun N-terminal kinase. J Biol Chem 2003, in press.
43. Tretter L., Ronai E., Szabados G., Hermann R., Ando A., Horvath I. The effect of the radioprotector WR-2721 and WR-1065 on mitochondrial lipid peroxidation. Int. J. Radiat. Biol. 57:1990;467-478.
44. Grdina D.J., Shigematsu N., Dale P., Newton G.L., Aguilera J.A., Fahey R.C. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis. 16:1995;767-774.
45. Chen Y.R., Shrivastava A., Tan T.H. Down-regulation of the c-Jun N-terminal kinase (JNK) phosphatase M3/6 and activation of JNK by hydrogen peroxide and pyrrolidine dithiocarbamate. Oncogene. 20:2001;367-374.
46. Gomez D.A., Martinez-Martinez S., Calvo V., Armesilla A.L., Redondo J.M. JNK (c-Jun NH2-terminal kinase) is a target for antioxidants in T lymphocytes. J. Biol. Chem. 271:1996;26335-26340.
47. Wang T., Arifoglu P., Ronai Z., Tew K.D. Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J. Biol. Chem. 276:2001;20999-21003.
48. Lackinger D., Eichhorn U., Kaina B. Effect of ultraviolet light, methyl methanesulfonate and ionizing radiation on the genotoxic response and apoptosis of mouse fibroblasts lacking c-Fos, p53 or both. Mutagenesis. 16:2001;233-241.